Rock Springs Capital Management LP Has $32.40 Million Stake in Enliven Therapeutics, Inc. $ELVN

Rock Springs Capital Management LP lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 3.5% in the 1st quarter, HoldingsChannel.com reports. The fund owned 826,500 shares of the company’s stock after purchasing an additional 28,095 shares during the quarter. Enliven Therapeutics comprises approximately 1.9% of Rock Springs Capital Management LP’s holdings, making the stock its 15th biggest position. Rock Springs Capital Management LP’s holdings in Enliven Therapeutics were worth $32,399,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ELVN. KBC Group NV acquired a new stake in Enliven Therapeutics during the 1st quarter valued at $38,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Enliven Therapeutics during the 4th quarter worth about $83,000. Finally, Quantbot Technologies LP boosted its holdings in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the period. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

ELVN opened at $52.74 on Tuesday. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $55.79. The company has a market capitalization of $3.21 billion, a P/E ratio of -31.58 and a beta of 0.24. The stock has a fifty day moving average of $45.75 and a 200-day moving average of $37.69.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06. On average, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Mizuho upped their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. JonesTrading raised their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. HC Wainwright boosted their price objective on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Finally, Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $70.50.

Insider Activity

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the sale, the director owned 41,884 shares of the company’s stock, valued at $2,114,723.16. The trade was a 19.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the completion of the sale, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at $2,233,800. This represents a 10.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,018 shares of company stock valued at $1,113,888 in the last quarter. Corporate insiders own 3.00% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.